Name: Resonance Health (RHT) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

RHT

Resonance Health

Health Care Equipment & Services

Resonance Health is a MedTech company specializing in non-invasive medical imaging analysis, particularly in iron overload and liver disease management. Their portfolio includes post-MRI analysis tools like FerriScan and HepaFatScan, providing quantitative calculations and evaluations essential for disease management and clinical trials.

Short position

short percentage0.02%

reported shorts71.8K

shares on issue477.120M

Resonance Health (ASX:RHT) has 0.02% of its shares on issue reported as short positions as of 25 Sept 2026, or about 71,783 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.23% in February 2019. RHT is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Weekly context: The 10 most shorted ASX stocks — Week 39, 2026.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

RHT intelligence dossier

Public-source evidence for this company, with industry drill-up links.

Tax paid and taxable income records
Government contracts and public money
Emissions and trade exposure
Political donations and lobbying links

Short interest history & FAQ

RHT Short Interest History

30-day change: +0.01pp
90-day change: +0.01pp
1-year change: +0.01pp
All-time high: 0.23% (February 2019)
All-time low: 0.00% (February 2014)

Is RHT heavily shorted?

Not especially: 0.02% short interest is modest by ASX standards, ranking #574 of 811 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.

How has RHT's short interest changed recently?

Over the past 30 days Resonance Health's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.02% of shares on issue.

What is the highest RHT's short interest has been?

Since 2014, Resonance Health's short interest peaked at 0.23% in February 2019 and bottomed at 0.00% in February 2014.

Where does this data come from?

All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2014. See our methodology.

RHT fundamentals

In the year to 30 Jun 2026, Resonance Health (ASX:RHT) recorded revenue of A$15.8M and net profit after tax of A$1.5M. A year earlier it recorded revenue of A$11.2M and a net loss after tax of A$1.7M. Year-on-year growth: revenue +41.3% (FY). Net margin 9.6% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit), as at 29 Sep 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Strategy fit

How each stock picker strategy reads RHT today

PassFailUnknown (data missing, or not meaningful for this company)

Zanger Breakout
WatchScore 62rank 8 of 1982
- 1. Explosive growth: pass. Revenue +41.3% YoY (FY ending 2026-06-30), accelerating from +29.9%; EPS swung from a loss to a profit (12 months to 2026-06-30)
- 2. A recognisable base: pass. 24-session base, 23.2% deep; close A$0.07 holds above the base low A$0.05
- 3. Breakout on heavy volume: pass. Broke out on 2026-09-29: a close above the prior 40-session high on at least 1.5x average volume; pivot A$0.07
- 4. Read the market first: fail. XJO in a downtrend: below its 200-day average
- 5. Relative strength: pass. Beat the S&P/ASX 200 by 52.4 points over 3 months
- 6. Liquid enough to trade: fail. A$20k average daily turnover over 20 sessions, below the A$250k floor
CAN SLIM
WatchScore 43rank 89 of 1533
- 1. Earnings growth (C and A): pass. EPS swung from a loss to a profit (12 months to 2026-06-30)
- 2. Sales growth: pass. Revenue +41.3% YoY (FY ending 2026-06-30), accelerating from +29.9%
- 3. New highs (N): fail. 9.3% below the 52-week high, more than 5% away
- 4. Leader, not laggard (L): pass. 6-month relative strength +69.6 points, in the top quartile (cut-off +6.5)
- 5. Market direction (M): fail. XJO in a downtrend: below its 200-day average
- 6. Supply and demand (S): fail. A$20k average daily turnover over 20 sessions, below the A$250k floor
Minervini Trend Template
WatchScore 73rank 142 of 1801
- 1. Above rising averages: pass. Close A$0.07, 150-day A$0.05, 200-day A$0.05: stacked in order
- 2. 200-day trending up: pass. 200-day average A$0.05 vs A$0.05 a month ago (+3.2%)
- 3. Well off the low: pass. Close A$0.07 is 94.3% above the 52-week low of A$0.04
- 4. Near the high: pass. 9.3% below the 52-week high
- 5. Relative strength: pass. 6-month relative strength +69.6 points, in the top quartile (cut-off +6.5)
- 6. Above the 50-day: pass. Close A$0.07 vs 50-day average A$0.06 (+13.1%)
- 7. Liquid enough to trade: fail. A$20k average daily turnover over 20 sessions, below the A$250k floor
Crowded-Short Breakout
WatchScore 37rank 96 of 1595
- 1. Crowded short: fail. 0.02% of shares on issue reported short, under 5%
- 2. Days to cover: fail. 0.2 days of average volume to cover, under 5
- 3. Breakout on heavy volume: pass. Broke out on 2026-09-29: a close above the prior 40-session high on at least 1.5x average volume; pivot A$0.07
- 4. Market direction: fail. XJO in a downtrend: below its 200-day average
- 5. Liquid enough to trade: fail. A$20k average daily turnover over 20 sessions, below the A$250k floor
- 6. Relative strength: pass. Beat the S&P/ASX 200 by 52.4 points over 3 months
Quality compounders
WatchScore 40rank 248 of 1687
- 1. High return on equity: unknown. Return on equity cannot be measured: it needs net profit, equity at both ends of the year and, outside banks, insurers and other financials, equity of at least 10% of total assets
- 2. Healthy profit margin: fail. Net margin 9.6% (FY ending 2026-06-30), below the 10% threshold
- 3. Profit that turns into cash: pass. Free cash flow is 1.71x net profit (FY ending 2026-06-30)
- 4. Little debt: unknown. Net debt cannot be measured: no aligned balance sheet with debt and cash
- 5. Liquid enough to trade: fail. A$20k average daily turnover over 20 sessions, below the A$250k floor
- 6. Long-term uptrend: pass. Close A$0.07 vs 200-day average A$0.05 (+42.7%)
- 7. Revenue not shrinking: pass. Revenue +41.3% YoY (FY ending 2026-06-30), accelerating from +29.9%